EXEL - エクセリクス （Exelixis Inc.） エクセリクスEXELのチャート
EXELの企業情報
| symbol | EXEL |
|---|---|
| 会社名 | Exelixis Inc （エクセリクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Commercial Physical_Biological Resarch |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 エクセチクス（Exelixis Inc.）は癌の低分子療法の開発に取り組むバイオ企業。同社はcabozantinib（カボザンチニブ）（XL184）に資源を投入し、それの開発を集中する。同社は他の化合物製品も有する。カボザンチニブは臨床開発段階にあるMETの阻害剤で、複数の癌の適応症を包含する開発プログラムで査定される。カボザンチニブの臨床プログラムは転移性去勢抵抗性前立腺癌（CRPC）と甲状腺髄様癌の治療に集中し、他のタイプの腫瘍の査定も含む。カボザンチニブは腫瘍の増殖、血管侵入および/または転移のキードライバーであるタンパク質のMET、血管内皮増殖因子受容体２（VEGFR2）、及びトランスフェクション中の再構成（RET）を抑制する。 エクセリクスは米国のバイオ医薬品メ―カ―。主にがん治療のための小分子治療薬の開発、製品化に従事。進行性・転移性甲状腺髄様癌の治療薬「COMETRIO」(カボザンチニブ)に焦点を当てた臨床活動を行う。同社は1994年に設立され、カリフォルニア州サウスサンフランシスコに本社を置く。 Founded in 1994, Exelixis, Inc. is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model system genetics, it established a broad drug discovery and development platform that has served as the foundation for its continued efforts to bring new cancer therapies to patients in need. Its discovery efforts have resulted in four commercially available products, CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib), COTELLIC® (cobimetinib) and MINNEBRO® (esaxerenone), and it has entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from its marketed products and collaborations, it is committed to prudently reinvesting in its business to maximize the potential of its pipeline. It is supplementing its existing therapeutic assets with targeted business development activities and internal drug discovery - all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. Exelixis is a member of the Standard & Poor's (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies. In November 2020, the company was named to Fortune's 100 Fastest-Growing Companies list for the first time, ranking 17th overall and the third-highest biopharmaceutical company. |
| 本社所在地 | 1851 Harbor Bay Parkway Alameda CA 94502 USA |
| 代表者氏名 | Stelios Papadopoulos Stelios Papadopoulos |
| 代表者役職名 | Independent Chairman of the Board Co-Founder |
| 電話番号 | +1 650-837-7000 |
| 設立年月日 | 34639 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2000年 |
| 従業員数 | 372人 |
| url | www.exelixis.com |
| nasdaq_url | https://www.nasdaq.com/symbol/exel |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 322.48800 |
| 終値（lastsale） | 17.35 |
| 時価総額（marketcap） | 5170915196.3 |
| 時価総額 | 時価総額（百万ドル） 5206.68 |
| 売上高 | 売上高（百万ドル） 671.03600 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 4727.403 |
| 当期純利益 | 当期純利益（百万ドル） 323.22200 |
| 決算概要 | 決算概要 BRIEF: For the 26 weeks ended 30 June 2018 Exelixis Inc. revenues increased from $179.9M to $398.5M. Net income increased from $34.4M to $203.4M. Revenues reflect Net product revenues increase of 79% to $280.1M Collaboration revenues increase from $23M to $118.3M. Net income benefited from Interest expense decrease from $8.7M (expense) to $0K Interest Income increase of 71% to $4.6M (income). |
EXELのテクニカル分析
EXELのニュース
Farallon steps up activism at biotech company Exelixis. Heres what could happen next 2023/04/15 11:26:07 CNBC
Farallon isnt an activist investor, but it wont shy away from a battle if necessary.
Farallon steps up activism at biotech company Exelixis. Here’s what could happen next 2023/04/15 11:26:00 CNBC
Farallon isn’t an activist investor, but it won’t shy away from a battle if necessary.
Exelexis supports two of Farallon''s board nominees as it faces proxy fight 2023/04/13 21:16:58 Seeking Alpha
Exelixis (EXEL) supports two of investor Farallon''s board nominees even as the investor last week said it planned to pursue a proxy fight with the biotech firm.Exelixis (EXEL) said…
Head and Neck Cancer Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032), States DelveInsight | Key Companies - Merck KGaA, Adlai Nortye Biopharma, HoffmannLa Roche, Exelixis, Immutep, Takeda, Amgen 2023/04/13 10:57:32 OpenPR
DelveInsight''s "Head and Neck Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Head and Neck Cancer, historical and forecasted epidemiology as well as the Head and Neck Cancer market trends in the United States,
Morgan Stanley maintains Exelixis at Equalweight 2023/04/12 15:03:37 Investing.com
https://www.investing.com/news/pro/exelixis-inc-receives-investment-bank-analyst-rating-update-3053806
Exelixis Inc.: Cancer Crusader With A Bright Future 2023/02/28 08:10:08 Seeking Alpha
Exelixis deals in the development and commercialization of cancer-related treatments and drugs. Read why I consider EXEL stock as a Buy now.
Mid-Day Stocks in Focus: Exelixis, Inc. (NASDAQ:EXEL), TEGNA Inc. (NYSE:TGNA) 2023/02/22 17:57:07 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Mid-Day Stocks in Focus: Exelixis, Inc. (NASDAQ:EXEL), TEGNA Inc. (NYSE:TGNA) appeared first on Stocks Equity .
Current Stocks’s Buzzers: Exelixis, Inc. (NASDAQ:EXEL -0.23%), Kinross Gold Corporation (NYSE:KGC -0.52%) 2023/02/21 16:22:30 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Current Stocks’s Buzzers: Exelixis, Inc. (NASDAQ:EXEL -0.23%), Kinross Gold Corporation (NYSE:KGC -0.52%) appeared first on Stocks Equity .
Bristol Myers Opdivo, Exelixis/Ipsen''s Cabometyx combo shows survival benefit in kidney cancer in 3 year data 2023/02/14 10:59:48 Seeking Alpha
Three year data from a phase 3 trial showed sustained survival and response rate benefits with Bristol Myers Squibb''s (BMY) Opdivo and Exelixis and Ipsen''s (IPSEY) (IPSEF)…
Opdivo (nivolumab) in Combination with CABOMETYX (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma 2023/02/13 22:00:00 Wallstreet:Online
Bristol Myers Squibb (NYSE: BMY) and Exelixis, Inc. (NASDAQ: EXEL) today announced three-year (36.5 months minimum; 44.0 months median) follow-up results from the Phase 3 CheckMate -9ER trial, demonstrating sustained survival and response rate benefits with the combination of Opdivo (nivolumab) and CABOMETYX (cabozantinib) versus sunitinib in the first-line treatment of advanced renal cell carcinoma
Exelixis, Inc. (EXEL) Q4 2022 Earnings Call Transcript 2023/02/08 01:48:03 Seeking Alpha
Exelixis, Inc. (NASDAQ:NASDAQ:EXEL) Q4 2022 Results Conference Call February 7, 2023 5:00 PM ETCompany ParticipantsSusan Hubbard - EVP, Public Affairs and IRMike Morrissey - President and…
Exelixis: Q4 Earnings Snapshot 2023/02/07 21:59:03 WTOP
ALAMEDA, Calif. (AP) — ALAMEDA, Calif. (AP) — Exelixis Inc. (EXEL) on Tuesday reported a fourth-quarter loss of $30.2 million,…
Exelixis Tops Q4 EPS by 8c By Investing.com 2023/02/07 21:34:06 Investing.com
Exelixis Tops Q4 EPS by 8c
Exelixis Non-GAAP EPS of -$0.03 beats by $0.02, revenue of $423.92M beats by $5.21M (NASDAQ:EXEL) 2023/02/07 21:10:47 Seeking Alpha
Exelixis press release (EXEL): Q4 Non-GAAP EPS of -$0.03 beats by $0.02.Revenue of $423.92M (-6.0% Y/Y) beats by $5.21M.Cabozantinib franchise achieved $1.40 billion in U.S. Net…
Exelixis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update 2023/02/07 21:05:00 Exelixis
- Total Revenues of $423.9 million for the Fourth Quarter of 2022, $1.61 billion for the Full Year 2022 - - Cabozantinib franchise achieved $1.40 billion in U.S. Net Product Revenues for the Full Year 2022, including $377.4 million for the Fourth Quarter 2022 - - GAAP Diluted EPS of $(0.09) for the